Vaccine antibody check: how long does protection last?
NCT ID NCT06280157
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed women who previously received 1 to 3 doses of an experimental Group B Strep (GBS) vaccine. The goal was to see how long their immune antibodies lasted by taking yearly blood samples for 2 to 5 years. No new vaccine or treatment was given—only observation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
29 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
A minimum of 20 and a maximum of 55 female participants, all of whom received previous vaccination with GBS-NN/NN2 in the MVX0002 and MVX0003 studies, will be recruited.
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. 2. Able to voluntarily provide written informed consent to participate in the study. 3. Participant must be fit to participate in the study, as assessed by the investigator. 4. Participant must be able to comply with study procedures and provide at least 2 blood samples. Exclusion Criteria: 1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or MinervaX employees, including their family members. 2. Any known or suspected immunocompromising or immune suppressive condition (including conditions caused by certain immunocompromising/immunosuppressive medication), unless the condition is expected to normalise within 12 weeks after enrolment. If this is the case, then the subject can be enrolled but the blood sampling will be postponed until the condition has normalised. 3. Received systemic steroids in the 6 weeks before any blood sampling (inhaled and topical steroids are acceptable). 4. Received blood, blood products, plasma derivatives or any immunoglobulin preparations in the 12 weeks before any blood sampling. 5. While participants who are enrolled on this study will also be eligible for participation in other clinical trials which may be ongoing during the overall period of participation in this study, they are not allowed to participate in another vaccine study nor in a study involving a licensed or investigational drug which is known or suspected to have an impact on the immune response (immune compromising/suppressing/stimulating).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Group B streptococcus infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Simbec-Orion Clinical Pharmacology
Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom